Director's Dealing • Dec 11, 2025
Director's Dealing
Open in ViewerOpens in native device viewer
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Øystein Rekdal | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Chief Executive Officer | ||
| b) | Initial notification/Amendment |
Initial notification | ||
| 3 | Details of issuer | |||
| a) | Name | Lytix Biopharma AS | ||
| b) | LEI | 549300NXMIMRSBCDZO71 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||
| a) | Description of the financial instrument, type of instrument Identification code |
Shares in Lytix Biopharma AS (ISIN NO 0010405780) | ||
| b) | Nature of the transaction | Purchase of shares | ||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |
| NOK 9.9984 | 10,000.00 | |||
| d) | Aggregated information — Aggregated volume — Price |
Aggregated volume: 10,000.00 Total price: NOK 99,984.00 |
||
| e) | Date of the transaction | 2025-12-11 | ||
| f) | Place of the transaction | MERK - Euronext Growth Oslo |
/ 1
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.